Lixte Stock Performance

LIXT -  USA Stock  

USD 2.79  0.13  4.89%

Lixte Biotech has performance score of 1 on a scale of 0 to 100. The company secures a Beta (Market Risk) of 0.3355, which conveys possible diversification benefits within a given portfolio. Let's try to break down what Lixte's beta means in this case. As returns on the market increase, Lixte Biotech returns are expected to increase less than the market. However, during the bear market, the loss on holding Lixte Biotech will be expected to be smaller as well. Although it is extremely important to respect Lixte Biotech Hlds price patterns, it is better to be realistic regarding the information on equity historical price patterns. The philosophy towards estimating future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By analyzing Lixte Biotech Hlds technical indicators, you can presently evaluate if the expected return of 0.12% will be sustainable into the future. Lixte Biotech Hlds right now secures a risk of 4.51%. Please verify Lixte Biotech Hlds treynor ratio, expected short fall, as well as the relationship between the Expected Short fall and day median price to decide if Lixte Biotech Hlds will be following its current price movements.

Search Stock Performance 

 
Refresh
 Lixte Performance
1 of 100
Compared to the overall equity markets, risk-adjusted returns on investments in Lixte Biotech Hlds are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively conflicting basic indicators, Lixte Biotech may actually be approaching a critical reversion point that can send shares even higher in August 2021. ...more

Lixte Price Channel

Quick Ratio31.93
Fifty Two Week Low0.7500
Fifty Two Week High7.1900

Lixte Biotech Relative Risk vs. Return Landscape

If you would invest  276.00  in Lixte Biotech Hlds on April 30, 2021 and sell it today you would earn a total of  3.00  from holding Lixte Biotech Hlds or generate 1.09% return on investment over 90 days. Lixte Biotech Hlds is currently generating 0.1181% in daily expected returns and assumes 4.5133% risk (volatility on return distribution) over the 90 days horizon. In different words, 38% of stocks are less volatile than Lixte, and 98% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
 Daily Expected Return (%) 
      Risk (%) 
Given the investment horizon of 90 days Lixte Biotech is expected to generate 6.08 times more return on investment than the market. However, the company is 6.08 times more volatile than its market benchmark. It trades about 0.03 of its potential returns per unit of risk. The DOW is currently generating roughly 0.08 per unit of risk.

Lixte Biotech Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Lixte Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Lixte Biotech Hlds, and traders can use it to determine the average amount a Lixte Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.0262

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
LIXTHuge
Risk
Negative Returns
Estimated Market Risk
 4.51
  actual daily
 
 38 %
of total potential
 
3838
Expected Return
 0.12
  actual daily
 
 2 %
of total potential
 
22
Risk-Adjusted Return
 0.03
  actual daily
 
 1 %
of total potential
 
11
Based on monthly moving average Lixte Biotech is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Lixte Biotech by adding it to a well-diversified portfolio.

About Lixte Biotech Performance

To evaluate Lixte Biotech Hlds Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Lixte Biotech generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Lixte Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Lixte Biotech Hlds stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents Lixte's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company was incorporated in 2005 and is based in East Setauket, New York. Lixte Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.

Things to note about Lixte Biotech Hlds

Checking the ongoing alerts about Lixte Biotech for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Lixte Biotech Hlds help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Lixte Biotech Alerts

Equity Alerts and Improvement Suggestions

Lixte Biotech Hlds has very high historical volatility over the last 90 days
Lixte Biotech Hlds has a very high chance of going through financial distress in the upcoming years
The company reported the previous year's revenue of 200 K. Net Loss for the year was (4.61 M) with profit before overhead, payroll, taxes, and interest of 0.
Lixte Biotech Hlds currently holds about 7.74 M in cash with (2.74 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.57.
Roughly 68.0% of the company outstanding shares are owned by corporate insiders
Latest headline from MacroaxisInsider: Lixte Biotech exotic insider transaction detected
Additionally, see Stocks Correlation. Note that the Lixte Biotech Hlds information on this page should be used as a complementary analysis to other Lixte Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Rebalancing module to analyze risk-adjusted returns against different time horizons to find asset-allocation targets.

Complementary Tools for Lixte Stock analysis

When running Lixte Biotech Hlds price analysis, check to measure Lixte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lixte Biotech is operating at the current time. Most of Lixte Biotech's value examination focuses on studying past and present price action to predict the probability of Lixte Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Lixte Biotech's price. Additionally, you may evaluate how the addition of Lixte Biotech to your portfolios can decrease your overall portfolio volatility.
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Bollinger Bands
Use Bollinger Bands indicator to analyze target price for a given investing horizon
Go
Fundamental Analysis
View fundamental data based on most recent published financial statements
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
The market value of Lixte Biotech Hlds is measured differently than its book value, which is the value of Lixte that is recorded on the company's balance sheet. Investors also form their own opinion of Lixte Biotech's value that differs from its market value or its book value, called intrinsic value, which is Lixte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lixte Biotech's market value can be influenced by many factors that don't directly affect Lixte Biotech Hlds underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lixte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Lixte Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lixte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.